StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Candel Therapeutics's price to book ratio was 5.6× on Nov 11, 2026, against 3.3× a year earlier. Over the last 5 years it ranged from 0.8× to 43.7×, with a median of 3.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.6×+1.7
2025Dec 31, 20253.9×−25.2
2024Jul 31, 202429.1×+27.3
2023Dec 29, 20231.8×+0.9
2022Dec 30, 20221.0×−2.6
2021Dec 31, 20213.6×–

More Candel Therapeutics figures

See a number that looks wrong?